BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, Schnitzler MA, Gheorghian A, Salvalaggio PR, Segev DL. MELD Exceptions and Rates of Waiting List Outcomes. Am J Transplant. 2011;11:2362-2371. [PMID: 21920019 DOI: 10.1111/j.1600-6143.2011.03735.x] [Cited by in Crossref: 154] [Cited by in F6Publishing: 123] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Parikh ND, Marrero WJ, Sonnenday CJ, Lok AS, Hutton DW, Lavieri MS. Population-Based Analysis and Projections of Liver Supply Under Redistricting. Transplantation 2017;101:2048-55. [DOI: 10.1097/tp.0000000000001785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
2 Ghabril M, Charlton M. Lack of Survival Benefit Following Liver Transplantation With MELD Exception Points for Hepatocellular Carcinoma: Beyond the Unblinding of Lady Justice. Gastroenterology 2015;149:531-4. [PMID: 26226568 DOI: 10.1053/j.gastro.2015.07.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Al-judaibi B, Alqalami I, Sey M, Qumosani K, Howes N, Sinclair L, Chandok N, Eddin AH, Hernandez-alejandro R, Marotta P, Teriaky A. Exercise Training for Liver Transplant Candidates. Transplantation Proceedings 2019;51:3330-7. [DOI: 10.1016/j.transproceed.2019.08.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Haugen CE, Ishaque T, Sapirstein A, Cauneac A, Segev DL, Gentry S. Geographic disparities in liver supply/demand ratio within fixed-distance and fixed-population circles. Am J Transplant 2019;19:2044-52. [PMID: 30748095 DOI: 10.1111/ajt.15297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Bazerbachi F, Aby E, Lake JR. Selecting patients with hepatocellular carcinoma for liver transplantation: Who should receive priority?: Editorial. Liver Transpl 2013;19:1289-91. [DOI: 10.1002/lt.23791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Dodson RM, He J, Pawlik TM. Resection and transplantation for hepatocellular carcinoma: factors influencing surgical options. Future Oncology 2014;10:587-607. [DOI: 10.2217/fon.13.225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
7 Goldberg DS, Makar G, Bittermann T, French B. Center variation in the use of nonstandardized model for end-stage liver disease exception points. Liver Transpl. 2013;19:1330-1342. [PMID: 24039090 DOI: 10.1002/lt.23732] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
8 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
9 Gentry SE, Chow EK, Wickliffe CE, Massie AB, Leighton T, Segev DL. Impact of broader sharing on the transport time for deceased donor livers. Liver Transpl 2014;20:1237-43. [PMID: 24975028 DOI: 10.1002/lt.23942] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
10 Mclean KA, Camilleri-brennan J, Knight SR, Drake TM, Ots R, Shaw CA, Wigmore SJ, Harrison EM. Decision modeling in donation after circulatory death liver transplantation. Liver Transpl 2017;23:594-603. [DOI: 10.1002/lt.24715] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
11 Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology 2020;98:836-46. [PMID: 33027788 DOI: 10.1159/000502482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zaccaria R, Teti G, Mecule A, Torlone N, Valeri M, Adorno D. Liver Graft Allocation by Means of a New, Regionally Shared "Mixed" Model: The Experience in Lazio. Transplant Proc 2015;47:2113-5. [PMID: 26361656 DOI: 10.1016/j.transproceed.2014.11.075] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Gentry SE, Massie AB, Cheek SW, Lentine KL, Chow EH, Wickliffe CE, Dzebashvili N, Salvalaggio PR, Schnitzler MA, Axelrod DA. Addressing geographic disparities in liver transplantation through redistricting. Am J Transplant. 2013;13:2052-2058. [PMID: 23837931 DOI: 10.1111/ajt.12301] [Cited by in Crossref: 120] [Cited by in F6Publishing: 90] [Article Influence: 13.3] [Reference Citation Analysis]
14 Arruda S, Chedid MF, Jacinto MM, Álvares-DA-Silva MR. MELD EXCEPTION POINTS PROVIDE AN ENOURMOUS ADVANTAGE FOR RECEIVING A LIVER TRANSPLANT IN BRAZIL. Arq Gastroenterol 2020;57:254-61. [PMID: 32935744 DOI: 10.1590/S0004-2803.202000000-48] [Reference Citation Analysis]
15 Massie AB, Kucirka LM, Segev DL. Big data in organ transplantation: registries and administrative claims. Am J Transplant 2014;14:1723-30. [PMID: 25040084 DOI: 10.1111/ajt.12777] [Cited by in Crossref: 178] [Cited by in F6Publishing: 166] [Article Influence: 25.4] [Reference Citation Analysis]
16 Latt NL, Niazi M, Pyrsopoulos NT. Liver transplant allocation policies and outcomes in United States: A comprehensive review. World J Methodol 2022; 12(1): 32-42 [DOI: 10.5662/wjm.v12.i1.32] [Reference Citation Analysis]
17 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 138] [Article Influence: 18.1] [Reference Citation Analysis]
18 Heimbach JK. United States liver allocation. Current Opinion in Organ Transplantation 2020;25:104-9. [DOI: 10.1097/mot.0000000000000740] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hart A, Schladt DP, Zeglin J, Pyke J, Kim WR, Lake JR, Roberts JP, Hirose R, Mulligan DC, Kasiske BL, Snyder JJ, Israni AK. Predicting Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation in Organ Availability and Priority Allocation Points. Transplantation 2016;100:2153-9. [PMID: 27490411 DOI: 10.1097/TP.0000000000001384] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
20 Agopian VG, Morshedi MM, Mcwilliams J, Harlander-locke MP, Markovic D, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Hiatt JR, Busuttil RW. Complete Pathologic Response to Pretransplant Locoregional Therapy for Hepatocellular Carcinoma Defines Cancer Cure After Liver Transplantation: Analysis of 501 Consecutively Treated Patients. Annals of Surgery 2015;262:536-45. [DOI: 10.1097/sla.0000000000001384] [Cited by in Crossref: 69] [Cited by in F6Publishing: 37] [Article Influence: 9.9] [Reference Citation Analysis]
21 Wey A, Noreen S, Gentry S, Cafarella M, Trotter J, Salkowski N, Segev D, Israni A, Kasiske B, Hirose R, Snyder J. The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses. Liver Transpl 2021. [PMID: 34482614 DOI: 10.1002/lt.26286] [Reference Citation Analysis]
22 Asrani SK, Kamath PS. Model for end-stage liver disease score and MELD exceptions: 15 years later. Hepatol Int. 2015;9:346-354. [PMID: 26016462 DOI: 10.1007/s12072-015-9631-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
23 Bhoori S, Mazzaferro V. Current challenges in liver transplantation for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:867-79. [DOI: 10.1016/j.bpg.2014.08.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
24 Kumari R, Sahu MK, Tripathy A, Uthansingh K, Behera M. Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat Oncol 2018;5:HEP08. [PMID: 31293776 DOI: 10.2217/hep-2018-0002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
25 Ziogas IA, Hickman LA, Matsuoka LK, Izzy M, Montenovo MI, Rega SA, Feurer ID, Alexopoulos SP. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates. Liver Transpl. 2020;26:1112-1120. [PMID: 32475062 DOI: 10.1002/lt.25807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
26 Luo X, Mogul DB, Massie AB, Ishaque T, Bridges JFP, Segev DL. Predicting chance of liver transplantation for pediatric wait-list candidates. Pediatr Transplant 2019;23:e13542. [PMID: 31313464 DOI: 10.1111/petr.13542] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Stine JG, Northup PG, Stukenborg GJ, Cornella SL, Maluf DG, Pelletier SJ, Argo CK. Geographic variation in liver transplantation persists despite implementation of Share35: Regional disparities persist in liver transplantation. Hepatol Res 2018;48:225-32. [DOI: 10.1111/hepr.12922] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
28 Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902. [DOI: 10.1111/apt.12922] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
29 Vagefi PA, Dodge JL, Yao FY, Roberts JP. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015;21:187-194. [PMID: 25371243 DOI: 10.1002/lt.24042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
30 Bowring MG, Zhou S, Chow EKH, Massie AB, Segev DL, Gentry SE. Geographic Disparity in Deceased Donor Liver Transplant Rates Following Share 35. Transplantation 2019;103:2113-20. [PMID: 30801545 DOI: 10.1097/TP.0000000000002643] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 5.5] [Reference Citation Analysis]
31 Roberts DE, Kakar S, Mehta N, Gill RM. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence. Am J Surg Pathol 2018;42:855-65. [PMID: 29649017 DOI: 10.1097/PAS.0000000000001053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
32 Potretzke TA, Tan BR, Doyle MB, Brunt EM, Heiken JP, Fowler KJ. Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases. AJR Am J Roentgenol. 2016;207:25-31. [PMID: 26866746 DOI: 10.2214/ajr.15.14997] [Cited by in Crossref: 66] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
33 Ibáñez Samaniego L, Pérez Valderas M, Fernández Yunquera A, Rincón Rodríguez D, López Baena JA, Matilla Peña A, Catalina Rodríguez MV, Clemente Ricote G, Bañares Cañizares R, Salcedo Plaza M. Management of liver transplantation waiting list for decompensated cirrhosis in a Spanish tertiary hospital: differences between hepatitis C virus recipients and other etiologies. Transplant Proc 2014;46:3084-6. [PMID: 25420829 DOI: 10.1016/j.transproceed.2014.09.175] [Reference Citation Analysis]
34 Schiano T. MELD-good for many, not as good for others … at least for now. Hepatol Int 2013;7:306-8. [PMID: 26201766 DOI: 10.1007/s12072-012-9393-0] [Reference Citation Analysis]
35 Kornberg A, Witt U, Matevossian E, Küpper B, Assfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One. 2013;8:e53960. [PMID: 23349774 DOI: 10.1371/journal.pone.0053960] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
36 Goldberg D, French B, Abt P, Feng S, Cameron AM. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl. 2012;18:434-443. [PMID: 22271656 DOI: 10.1002/lt.23394] [Cited by in Crossref: 107] [Cited by in F6Publishing: 95] [Article Influence: 10.7] [Reference Citation Analysis]
37 Ebel NH, Hsu EK, Berry K, Horslen SP, Ioannou GN. Disparities in Waitlist and Posttransplantation Outcomes in Liver Transplant Registrants and Recipients Aged 18 to 24 Years: Analysis of the UNOS Database. Transplantation 2017;101:1616-27. [PMID: 28230640 DOI: 10.1097/TP.0000000000001689] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
38 Ladin K, Hanto DW. Are geographic differences in transplantation inherently wrong? Curr Opin Organ Transplant 2017;22:174-8. [PMID: 28151810 DOI: 10.1097/MOT.0000000000000400] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
39 Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl 2019;25:228-41. [DOI: 10.1002/lt.25333] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
40 Gentry S, Chow E, Massie A, Segev D. Gerrymandering for Justice: Redistricting U.S. Liver Allocation. Interfaces (Providence) 2015;45:462-80. [PMID: 34421152 DOI: 10.1287/inte.2015.0810] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
41 Zhou K, Mehta N. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient. Clin Liver Dis 2020;24:665-79. [PMID: 33012452 DOI: 10.1016/j.cld.2020.07.005] [Reference Citation Analysis]
42 Mustian MN, Shelton BA, MacLennan PA, Reed RD, White JA, Eckhoff DE, Locke JE, Allman RM, Gray SH. Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates. Transplantation 2019;103:1425-32. [PMID: 30418427 DOI: 10.1097/TP.0000000000002523] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
43 Kokabi N, Nezami N, Xing M, Ludwig JM, Strazzabosco M, Kim HS. Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma. J Comp Eff Res 2019;8:993-1002. [PMID: 31512955 DOI: 10.2217/cer-2019-0076] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Braun HJ, Perito ER, Dodge JL, Rhee S, Roberts JP. Nonstandard Exception Requests Impact Outcomes for Pediatric Liver Transplant Candidates. Am J Transplant 2016;16:3181-91. [PMID: 27214757 DOI: 10.1111/ajt.13879] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
45 Zhou K, Dodge JL, Xu E, Emamaullee J, Kahn JA. Excess liver transplant waitlist mortality for patients with primary biliary cholangitis under MELD-Na allocation. Clin Transplant 2021;:e14527. [PMID: 34731515 DOI: 10.1111/ctr.14527] [Reference Citation Analysis]
46 Pillai A, Couri T, Charlton M. Liver Allocation Policies in the USA: Past, Present, and the Future. Dig Dis Sci 2019;64:985-92. [DOI: 10.1007/s10620-019-05549-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
47 Mas VR. Ischemia/reperfusion, does temperature matter? Laboratory perspective. Liver Transpl 2015;21 Suppl 1:S1-5. [PMID: 26334928 DOI: 10.1002/lt.24322] [Reference Citation Analysis]
48 Li C, Zhu W, Wen T, Dai Y, Yan L, Li B, Yang J, Wang W, Xu M. Child-Pugh A Hepatitis B-Related Cirrhotic Patients with a Single Hepatocellular Carcinoma Up to 5 cm: Liver Transplantation vs. Resection. J Gastrointest Surg 2014;18:1469-76. [DOI: 10.1007/s11605-014-2550-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
49 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
50 Beal EW, Tumin D, Sobotka L, Tobias JD, Hayes D Jr, Pawlik TM, Washburn K, Mumtaz K, Conteh L, Black SM. Patients From Appalachia Have Reduced Access to Liver Transplantation After Wait-Listing. Prog Transplant 2018;28:305-13. [PMID: 30205758 DOI: 10.1177/1526924818800037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Goldberg DS, Olthoff KM. Standardizing MELD exceptions: Current challenges and future directions. Curr Transplant Rep. 2014;1:232-237. [PMID: 25530936 DOI: 10.1007/s40472-014-0027-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
52 Ladin K, Wang R, Fleishman A, Boger M, Rodrigue JR. Does Social Capital Explain Community-Level Differences in Organ Donor Designation? Milbank Q 2015;93:609-41. [PMID: 26350932 DOI: 10.1111/1468-0009.12139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
53 Massie AB, Chow EK, Wickliffe CE, Luo X, Gentry SE, Mulligan DC, Segev DL. Early changes in liver distribution following implementation of Share 35. Am J Transplant 2015;15:659-67. [PMID: 25693474 DOI: 10.1111/ajt.13099] [Cited by in Crossref: 85] [Cited by in F6Publishing: 67] [Article Influence: 12.1] [Reference Citation Analysis]
54 Croome KP, Lee DD, Harnois D, Taner CB. Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma. PLoS One 2017;12:e0170673. [PMID: 28122003 DOI: 10.1371/journal.pone.0170673] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
55 Gentry SE, Chow EK, Dzebisashvili N, Schnitzler MA, Lentine KL, Wickliffe CE, Shteyn E, Pyke J, Israni A, Kasiske B, Segev DL, Axelrod DA. The Impact of Redistricting Proposals on Health Care Expenditures for Liver Transplant Candidates and Recipients. Am J Transplant 2016;16:583-93. [PMID: 26779694 DOI: 10.1111/ajt.13569] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
56 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
57 Annamalai A, Ayoub W, Sundaram V, Klein A. First Look: One Year Since Inception of Regional Share 35 Policy. Transplant Proc 2015;47:1585-90. [PMID: 26293017 DOI: 10.1016/j.transproceed.2015.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
58 Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol 2021;74:829-37. [PMID: 33188904 DOI: 10.1016/j.jhep.2020.10.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
59 Hoyer DP, Paul A, Saner F, Gallinat A, Mathé Z, Treckmann JW, Schulze M, Kaiser GM, Canbay A, Molmenti E, Sotiropoulos GC. Safely expanding the donor pool: brain dead donors with history of temporary cardiac arrest. Liver Int 2015;35:1756-63. [DOI: 10.1111/liv.12766] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
60 Bittermann T, Goldberg DS. Liver redistricting: what are the upcoming changes in liver allocation in the United States? Current Opinion in Organ Transplantation 2017;22:112-7. [DOI: 10.1097/mot.0000000000000383] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
61 Luo X, Massie AB, Gentry SE, Segev DL. MELD allocation system: There is always space to improve. Am J Transplant 2018;18:2834-5. [PMID: 30052316 DOI: 10.1111/ajt.15036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Kalra A, Biggins SW. New paradigms for organ allocation and distribution in liver transplantation. Current Opinion in Gastroenterology 2018;34:123-31. [DOI: 10.1097/mog.0000000000000434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
63 Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant 2019;19:2210-8. [PMID: 30861298 DOI: 10.1111/ajt.15353] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
64 Nathan H, Segev DL, Bridges JFP, Massie AB, Cameron AM, Hirose K, Schulick RD, Choti MA, Pawlik TM. Influence of Nonclinical Factors on Choice of Therapy for Early Hepatocellular Carcinoma. Ann Surg Oncol 2013;20:448-56. [DOI: 10.1245/s10434-012-2619-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
65 Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013;19:1343-1353. [PMID: 24285611 DOI: 10.1002/lt.23753] [Cited by in Crossref: 103] [Cited by in F6Publishing: 83] [Article Influence: 12.9] [Reference Citation Analysis]
66 Jurado-García J, Muñoz García-Borruel M, Rodríguez-Perálvarez ML, Ruíz-Cuesta P, Poyato-González A, Barrera-Baena P, Fraga-Rivas E, Costán-Rodero G, Briceño-Delgado J, Montero-Álvarez JL, de la Mata-García M. Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality. PLoS One 2016;11:e0155822. [PMID: 27299728 DOI: 10.1371/journal.pone.0155822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017;101:2071-2078. [PMID: 28353492 DOI: 10.1097/tp.0000000000001752] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 7.6] [Reference Citation Analysis]
68 Yao FY. Conundrum of treatment for early-stage hepatocellular carcinoma: radiofrequency ablation instead of liver transplantation as the first-line treatment? Liver Transpl. 2014;20:257-260. [PMID: 24493329 DOI: 10.1002/lt.23848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
69 Stieger B, Heger M, de Graaf W, Paumgartner G, van Gulik T. The emerging role of transport systems in liver function tests. Eur J Pharmacol. 2012;675:1-5. [PMID: 22173125 DOI: 10.1016/j.ejphar.2011.11.048] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
70 Yohanathan L, Heimbach JK. The Impact of Allocation Changes on Patients with Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:657-63. [DOI: 10.1016/j.cld.2020.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Calmet FH, Samuel M, Martin P. PRO: Redistricting of United Network for Organ Sharing Regions to Improve Geographic Disparities in Liver Transplantation. Clin Liver Dis (Hoboken) 2018;12:60-4. [PMID: 30988912 DOI: 10.1002/cld.720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 7.4] [Reference Citation Analysis]
73 Sangiovanni A, Colombo M. A therapeutic conundrum: Delaying ablation of small nonresectable early hepatocellular carcinoma to facilitate liver transplantation. Liver Transpl 2016;22:161-2. [PMID: 26663560 DOI: 10.1002/lt.24382] [Reference Citation Analysis]
74 Almeida-Carvalho SR, Gomes-Ferraz ML, Loureiro-Matos CA, Benedito-Silva AT, Carvalho-Filho RJ, Renato-Perez R, Miziara-Gonzalez A, Salzedas-Netto AA, Szejnfeld D, D'Ippolito G, Pereira-Lanzoni V, Souza-Silva I. Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil. Ann Hepatol. 2017;16:255-262. [PMID: 28233747 DOI: 10.5604/16652681.1231584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
75 Ladin K, Zhang G, Hanto DW. Geographic Disparities in Liver Availability: Accidents of Geography, or Consequences of Poor Social Policy? Am J Transplant 2017;17:2277-84. [DOI: 10.1111/ajt.14301] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
76 Ishaque T, Kernodle AB, Motter JD, Jackson KR, Chiang TP, Getsin S, Boyarsky BJ, Garonzik-Wang J, Gentry SE, Segev DL, Massie AB. MELD is MELD is MELD? Transplant center-level variation in waitlist mortality for candidates with the same biological MELD. Am J Transplant 2021. [PMID: 33870635 DOI: 10.1111/ajt.16603] [Reference Citation Analysis]
77 Panayotova GG, Guarrera JV, Lunsford KE. Improving Patient Access to Liver Allografts Through a Mathematically Optimized Continuous Organ Distribution Model. Transplantation 2020;104:909-10. [PMID: 31634331 DOI: 10.1097/TP.0000000000003018] [Reference Citation Analysis]
78 Murali AR, Patil S, Phillips KT, Voigt MD. Locoregional Therapy With Curative Intent Versus Primary Liver Transplant for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis. Transplantation 2017;101:e249-57. [DOI: 10.1097/tp.0000000000001730] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 3.4] [Reference Citation Analysis]
79 Allen AM, Heimbach JK, Larson JJ, Mara KC, Kim WR, Kamath PS, Therneau TM. Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation 2018;102:1710-6. [PMID: 29620614 DOI: 10.1097/TP.0000000000002196] [Cited by in Crossref: 41] [Cited by in F6Publishing: 10] [Article Influence: 13.7] [Reference Citation Analysis]
80 Axelrod DA, Dzebisashvili N, Lentine K, Segev DL, Dickson R, Tuttle-Newhall E, Freeman R, Schnitzler M. Assessing variation in the costs of care among patients awaiting liver transplantation. Am J Transplant. 2014;14:70-78. [PMID: 24165015 DOI: 10.1111/ajt.12494] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
81 VanDerwerken DN, Wood NL, Segev DL, Gentry SE. The Precise Relationship Between Model for End-Stage Liver Disease and Survival Without a Liver Transplant. Hepatology 2021;74:950-60. [PMID: 33655565 DOI: 10.1002/hep.31781] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Lee E, Johnston CJC, Oniscu GC. The trials and tribulations of liver allocation. Transpl Int 2020;33:1343-52. [PMID: 32722866 DOI: 10.1111/tri.13710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Freeman RB Jr. Variation in health care delivery: the example of exception awards in liver transplantation. Am J Transplant 2011;11:2271-2. [PMID: 21920022 DOI: 10.1111/j.1600-6143.2011.03740.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
84 Terzi E, Ray Kim W, Sanchez W, Charlton MR, Schmeltzer P, Gores GJ, Andrews JC, Smyrk TC, Heimbach JK. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation: MULTIPLE TACE PROCEDURES. Liver Transpl 2015;21:248-57. [DOI: 10.1002/lt.24041] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
85 Brezeanu LN, Brezeanu RC, Diculescu M, Droc G. Anaesthesia for Liver Transplantation: An Update. J Crit Care Med (Targu Mures) 2020;6:91-100. [PMID: 32426515 DOI: 10.2478/jccm-2020-0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
86 Umgelter A, Hapfelmeier A, Kopp W, van Rosmalen M, Rogiers X, Guba M;  Eurotransplant Liver Advisory Committee. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions. Liver Transpl. 2017;23:1256-1265. [PMID: 28650098 DOI: 10.1002/lt.24805] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
87 Renz JF. The time to address the gorillas in the room is overdue. Liver Transpl 2013;19:1059-61. [PMID: 24039050 DOI: 10.1002/lt.23721] [Reference Citation Analysis]
88 Quante M, Benckert C, Thelen A, Jonas S. Experience Since MELD Implementation: How Does the New System Deliver? Int J Hepatol. 2012;2012:264015. [PMID: 23091734 DOI: 10.1155/2012/264015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
89 Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, Mcginnis J, Saab S, Beckerman R, Younossi ZM. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. Hepatology 2017;66:46-56. [DOI: 10.1002/hep.29137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
90 Deshpande R, Hirose R, Mulligan D. Liver allocation and distribution: time for a change. Current Opinion in Organ Transplantation 2017;22:162-8. [DOI: 10.1097/mot.0000000000000397] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 3.2] [Reference Citation Analysis]
91 Heimbach JK. Evolution of Liver Transplant Selection Criteria and U.S. Allocation Policy for Patients with Hepatocellular Carcinoma. Semin Liver Dis 2020;40:358-64. [PMID: 32942324 DOI: 10.1055/s-0040-1709492] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment. Curr Probl Diagn Radiol. 2015;44:479-486. [PMID: 25979220 DOI: 10.1067/j.cpradiol.2015.04.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
93 Voigt MD, Hunsicker LG, Snyder JJ, Israni AK, Kasiske BL. Regional Variability in Liver Waiting List Removals Causes False Ascertainment of Waiting List Deaths: False Ascertainment of Waiting List Deaths. American Journal of Transplantation 2013;13:369-75. [DOI: 10.1111/ajt.12000] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
94 Patel MS, Kohn R, Kratz JR, Shah JA, Markmann JF, Vagefi PA. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation. J Am Coll Surg 2015;220:1001-7. [PMID: 25868408 DOI: 10.1016/j.jamcollsurg.2014.12.050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
95 Hirose R. Liver Allograft Allocation and Distribution: Toward a More Equitable System. Curr Transpl Rep 2016;3:64-74. [DOI: 10.1007/s40472-016-0096-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl 2018;24:1346-56. [PMID: 30067889 DOI: 10.1002/lt.25317] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
97 Piñero F, Anders M, Boin IF, Chagas A, Quiñonez E, Marciano S, Vilatobá M, Santos L, Hoyos Duque S, Lima AS, Menendez J, Padilla M, Poniachik J, Zapata R, Soza A, Maraschio M, Chong Menéndez R, Muñoz L, Arufe D, Figueroa R, de Ataide EC, Maccali C, Vergara Sandoval R, Bermudez C, Podesta LG, McCormack L, Varón A, Gadano A, Mattera J, Villamil F, Rubinstein F, Carrilho F, Silva M. Liver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region. Transpl Int 2021;34:97-109. [PMID: 33040420 DOI: 10.1111/tri.13767] [Reference Citation Analysis]
98 Singal AK, Kamath PS. Model for End-stage Liver Disease. J Clin Exp Hepatol. 2013;3:50-60. [PMID: 25755471 DOI: 10.1016/j.jceh.2012.11.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
99 Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DM, Chung RT. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65:777-788. [PMID: 27906468 DOI: 10.1002/hep.28926] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 12.4] [Reference Citation Analysis]
100 Cejas NG, Villamil FG, Lendoire JC, Tagliafichi V, Lopez A, Krogh DH, Soratti CA, Bisigniano L. Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy. Liver Transpl. 2013;19:711-720. [PMID: 23775946 DOI: 10.1002/lt.23665] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
101 Oniscu GC, Diaz G, Levitsky J. Meeting report of the 19th Annual International Congress of the International Liver Transplantation Society (Sydney Convention and Exhibition Centre, Sydney, Australia, June 12-15, 2013). Liver Transpl 2014;20:7-14. [PMID: 24136728 DOI: 10.1002/lt.23767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
102 Heimbach JK, Hirose R, Stock PG, Schladt DP, Xiong H, Liu J, Olthoff KM, Harper A, Snyder JJ, Israni AK, Kasiske BL, Kim WR. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 2015;61:1643-50. [PMID: 25644186 DOI: 10.1002/hep.27704] [Cited by in Crossref: 84] [Cited by in F6Publishing: 68] [Article Influence: 12.0] [Reference Citation Analysis]
103 Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206-1213. [PMID: 29068145 DOI: 10.1111/ajt.14549] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
104 Lee HA, Cho EY, Kim TH, Lee Y, Suh SJ, Jung YK, Kim JH, An H, Seo YS, Kim DS, Yim HJ, Yeon JE, Byun KS, Um SH. Risk Factors for Dropout From the Liver Transplant Waiting List of Hepatocellular Carcinoma Patients Under Locoregional Treatment. Transplant Proc 2018;50:3521-6. [PMID: 30577230 DOI: 10.1016/j.transproceed.2018.08.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
105 Kensinger CD, Feurer ID, O'Dell HW, LaNeve DC, Simmons L, Pinson CW, Moore DE. Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma. Clin Transplant 2016;30:1036-45. [PMID: 27291713 DOI: 10.1111/ctr.12785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
106 Laique SN, Zhang N, Hewitt WR, Bajaj J, Vargas HE. Increased access to liver transplantation for patients with acute on chronic liver failure after implementation of Share 35 Rule: An analysis from the UNOS database. Ann Hepatol 2021;23:100288. [PMID: 33217586 DOI: 10.1016/j.aohep.2020.100288] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Martino RB, Waisberg DR, Dias APM, Inoue VBS, Arantes RM, Haddad LBP, Rocha-Santos V, Pinheiro RSN, Nacif LS, D'Albuquerque LAC. Access to Liver Transplantation in Different ABO-Blood Groups and "Exceptions Points" in a Model for End-Stage Liver Disease Allocation System: A Brazilian Single-Center Study. Transplant Proc 2018;50:754-7. [PMID: 29661430 DOI: 10.1016/j.transproceed.2018.02.020] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Gordon AC, Gabr A, Riaz A, Uddin OM, Abouchaleh N, Ali R, Kallini J, Salem R, Lewandowski RJ. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2018;41:1557-65. [PMID: 29948005 DOI: 10.1007/s00270-018-2008-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
109 Chang SH, Liu X, Carlsson NP, Park Y, Colditz GA, Garonzik-Wang JM, Chapman WC, Wellen JR, Doyle MB, Alhamad T. Reexamining the Association of Body Mass Index With Overall Survival Outcomes After Liver Transplantation. Transplant Direct 2017;3:e172. [PMID: 28706975 DOI: 10.1097/TXD.0000000000000681] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
110 Marvin MR, Ferguson N, Cannon RM, Jones CM, Brock GN. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma. Liver Transpl. 2015;21:612-622. [PMID: 25694099 DOI: 10.1002/lt.24098] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
111 Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, Haydel B, Hoteit M, Levine MH, Lee DD, Taner CB, Verna EC, Halazun KJ, Abdelmessih R, Tevar AD, Humar A, Aucejo F, Chapman WC, Vachharajani N, Nguyen MH, Melcher ML, Nydam TL, Mobley C, Ghobrial RM, Amundsen B, Markmann JF, Langnas AN, Carney CA, Berumen J, Hemming AW, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Busuttil RW. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg. 2017;266:525-535. [PMID: 28654545 DOI: 10.1097/sla.0000000000002381] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 12.6] [Reference Citation Analysis]
112 Keaveny AP, Taner CB. Prioritization for liver transplantation: Reconsidering survival benefit. Liver Transpl 2017;23:581-2. [PMID: 28192869 DOI: 10.1002/lt.24746] [Reference Citation Analysis]
113 Coelho GR, Praciano AM, Viana GNR, Lima CA, Feitosa Neto BA, Garcia JHP. Outcomes of Liver Transplant Recipients With Model for End-Stage Liver Disease Exception: Single-Center Experience in the Northeast of Brazil. Transplant Proc 2018;50:1428-30. [PMID: 29880366 DOI: 10.1016/j.transproceed.2018.03.003] [Reference Citation Analysis]
114 Croome KP, Lee DD, Burns JM, Keaveny AP, Taner CB. Intraregional model for end-stage liver disease score variation in liver transplantation: Disparity in our own backyard. Liver Transpl 2018;24:488-96. [DOI: 10.1002/lt.25021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
115 Vagefi PA, Bertsimas D, Hirose R, Trichakis N. The rise and fall of the model for end-stage liver disease score and the need for an optimized machine learning approach for liver allocation. Curr Opin Organ Transplant 2020;25:122-5. [PMID: 32073494 DOI: 10.1097/MOT.0000000000000734] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Kensinger CD, Feurer ID, Karp SJ. An Outcome-Based Approach to Assign MELD Exception Points for Patients With Hepatocellular Cancer. Transplantation 2017;101:2056-61. [DOI: 10.1097/tp.0000000000001812] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
117 Gentry SE, Chow EK, Massie A, Luo X, Shteyn E, Pyke J, Zaun D, Snyder JJ, Israni AK, Kasiske B, Segev DL. Liver sharing and organ procurement organization performance under redistricted allocation. Liver Transpl 2015;21:1031-9. [PMID: 25990089 DOI: 10.1002/lt.24171] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
118 Axelrod DA, Vagefi PA, Roberts JP. The Evolution of Organ Allocation for Liver Transplantation: Tackling Geographic Disparity Through Broader Sharing. Ann Surg 2015;262:224-7. [PMID: 26164429 DOI: 10.1097/SLA.0000000000001340] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
119 Schuetz C, Dong N, Smoot E, Elias N, Schoenfeld DA, Markmann JF, Yeh H. HCC patients suffer less from geographic differences in organ availability. Am J Transplant. 2013;13:2989-2995. [PMID: 24011291 DOI: 10.1111/ajt.12441] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
120 Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2-year results of "Share 35". Liver Transpl 2016;22:399-409. [PMID: 26890858 DOI: 10.1002/lt.24418] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
121 Lee DD, Burns JM, Perry DK, Nguyen JH, Keaveny AP, Taner CB. The migrated liver transplantation candidate: waitlist time affects mortality. J Am Coll Surg 2014;219:1099-100. [PMID: 25440035 DOI: 10.1016/j.jamcollsurg.2014.07.014] [Reference Citation Analysis]
122 Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM. Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology. 2007;46:1574-1585. [PMID: 17969047 DOI: 10.1002/hep.28139] [Cited by in Crossref: 82] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
123 Cannon RM, Davis EG, Goldberg DS, Lynch RJ, Shah MB, Locke JE, Mcmasters KM, Jones CM. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception. Journal of the American College of Surgeons 2020;230:503-512.e8. [DOI: 10.1016/j.jamcollsurg.2019.12.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol. 2019;17:739-747.e8. [PMID: 30138735 DOI: 10.1016/j.cgh.2018.08.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
125 Northup PG, Berg CL. Hepatocellular carcinoma and model for end-stage liver disease exceptions: the more we understand, the more challenging the allocation gets. Liver Transpl 2012;18:381-3. [PMID: 22323420 DOI: 10.1002/lt.23409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
126 Wedd JP. Model for end-stage liver disease exceptions: A common problem. Liver Transpl 2017;23:1251-2. [PMID: 28837747 DOI: 10.1002/lt.24857] [Reference Citation Analysis]
127 Bittermann T, Makar G, Goldberg D. Exception point applications for 15 points: an unintended consequence of the share 15 policy. Liver Transpl 2012;18:1302-9. [PMID: 22899664 DOI: 10.1002/lt.23537] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
128 Ishaque T, Massie AB, Bowring MG, Haugen CE, Ruck JM, Halpern SE, Waldram MM, Henderson ML, Garonzik Wang JM, Cameron AM, Philosophe B, Ottmann S, Rositch AF, Segev DL. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change. Am J Transplant 2019;19:564-72. [PMID: 30312530 DOI: 10.1111/ajt.15144] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
129 Bertsimas D, Kung J, Trichakis N, Wang Y, Hirose R, Vagefi PA. Development and validation of an optimized prediction of mortality for candidates awaiting liver transplantation. Am J Transplant 2018;19:1109-18. [DOI: 10.1111/ajt.15172] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
130 Cardoso FS, Karvellas CJ, Kneteman NM, Meeberg G, Fidalgo P, Bagshaw SM. Respiratory rate at intensive care unit discharge after liver transplant is an independent risk factor for intensive care unit readmission within the same hospital stay: a nested case-control study. J Crit Care 2014;29:791-6. [PMID: 24857401 DOI: 10.1016/j.jcrc.2014.03.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
131 Massie AB, Roberts JP. Geographic Disparity in Liver Allocation: Time to Act or Have Others Act for Us. Transplantation 2018;102:189-90. [DOI: 10.1097/tp.0000000000001993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DMS, Chung RT, Chhatwal J. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2018;16:115-122.e10. [PMID: 28634131 DOI: 10.1016/j.cgh.2017.06.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
133 Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short‐Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change. Liver Transpl 2020;26:662-72. [DOI: 10.1002/lt.25701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
134 Mahmud N, Gadsden MM, Goldberg DS. Is the Pediatric End-stage Liver Disease Score Truly a Detriment to Pediatric Liver Allocation? JAMA Pediatr 2018;172:1013-5. [PMID: 30242354 DOI: 10.1001/jamapediatrics.2018.2886] [Reference Citation Analysis]
135 Trapani S, Rizzato L, Masiero L, Ricci A, Morabito V, Peritore D, Fiaschetti P, Del Sordo E, Cacciotti AR, Montemurro A, Nanni Costa A. Hepatitis C Virus Positive Patients on the Waiting List for Liver Transplantation: Turnover and Characteristics of the Population on the Eve of the Therapeutic Revolution With Direct-Acting Antivirals. Transplant Proc 2017;49:658-66. [PMID: 28457366 DOI: 10.1016/j.transproceed.2017.02.039] [Reference Citation Analysis]
136 Salvalaggio PR. Geographic disparities in transplantation. Current Opinion in Organ Transplantation 2021;26:547-53. [DOI: 10.1097/mot.0000000000000914] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Goldberg DS, Fallon MB. Model for end-stage liver disease-based organ allocation: managing the exceptions to the rules. Clin Gastroenterol Hepatol 2013;11:452-3. [PMID: 23416221 DOI: 10.1016/j.cgh.2013.02.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
138 Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology. 2018;67:2085-2095. [PMID: 29222916 DOI: 10.1002/hep.29723] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
139 Gish RG, Wong RJ, Honerkamp-Smith G, Xu R, Osorio RW. United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board. Clin Transplant 2015;29:513-22. [PMID: 25808918 DOI: 10.1111/ctr.12544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
140 Lladó L, Bustamante J. IV Reunión de Consenso de la Sociedad Española de Trasplante Hepático 2012. Excepciones al Model for End-stage Liver Disease en la priorización para trasplante hepático. Gastroenterología y Hepatología 2014;37:83-91. [DOI: 10.1016/j.gastrohep.2013.06.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
141 Court CM, Harlander-Locke MP, Markovic D, French SW, Naini BV, Lu DS, Raman SS, Kaldas FM, Zarrinpar A, Farmer DG, Finn RS, Sadeghi S, Tomlinson JS, Busuttil RW, Agopian VG. Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection. Liver Transpl. 2017;23:1123-1132. [PMID: 28688158 DOI: 10.1002/lt.24811] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
142 Ivanics T, Patel MS, Erdman L, Sapisochin G. Artificial intelligence in transplantation (machine-learning classifiers and transplant oncology). Curr Opin Organ Transplant 2020;25:426-34. [PMID: 32487887 DOI: 10.1097/MOT.0000000000000773] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Massie AB, Luo X, Alejo JL, Poon AK, Cameron AM, Segev DL. Higher Mortality in registrants with sudden model for end-stage liver disease increase: Disadvantaged by the current allocation policy. Liver Transpl. 2015;21:683-689. [PMID: 25762287 DOI: 10.1002/lt.24102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]